Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1066937.RARugqegx1rehp2SzOiYFuA1TCHbuWUU8k4E3W6tVhZng130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1066937.RARugqegx1rehp2SzOiYFuA1TCHbuWUU8k4E3W6tVhZng130_assertion type Assertion NP1066937.RARugqegx1rehp2SzOiYFuA1TCHbuWUU8k4E3W6tVhZng130_head.
- NP1066937.RARugqegx1rehp2SzOiYFuA1TCHbuWUU8k4E3W6tVhZng130_assertion wasGeneratedBy ECO_0000203 NP1066937.RARugqegx1rehp2SzOiYFuA1TCHbuWUU8k4E3W6tVhZng130_provenance.
- NP1066937.RARugqegx1rehp2SzOiYFuA1TCHbuWUU8k4E3W6tVhZng130_assertion wasDerivedFrom befree-2016 NP1066937.RARugqegx1rehp2SzOiYFuA1TCHbuWUU8k4E3W6tVhZng130_provenance.
- NP1066937.RARugqegx1rehp2SzOiYFuA1TCHbuWUU8k4E3W6tVhZng130_assertion SIO_000772 23562183 NP1066937.RARugqegx1rehp2SzOiYFuA1TCHbuWUU8k4E3W6tVhZng130_provenance.
- NP1066937.RARugqegx1rehp2SzOiYFuA1TCHbuWUU8k4E3W6tVhZng130_assertion evidence source_evidence_literature NP1066937.RARugqegx1rehp2SzOiYFuA1TCHbuWUU8k4E3W6tVhZng130_provenance.
- NP1066937.RARugqegx1rehp2SzOiYFuA1TCHbuWUU8k4E3W6tVhZng130_assertion description "[The major recommendations are to use testing for EGFR mutations and ALK fusions to guide patient selection for therapy with an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitor, respectively, in all patients with advanced-stage adenocarcinoma, regardless of sex, race, smoking history, or other clinical risk factors, and to prioritize EGFR and ALK testing over other molecular predictive tests.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1066937.RARugqegx1rehp2SzOiYFuA1TCHbuWUU8k4E3W6tVhZng130_provenance.